arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Kura Oncology, Inc.

KURA
$10.87 ▼ -0.16 (-1.50%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
19 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
17
Health
Poor
Bearish
auto_awesome

Analytical Summary

Kura Oncology, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $953.0M
Dividend Yield —
Revenue Growth 25.2%
Op. Margin -449.9% ↘
ROIC -165.3% ↘
FCF / Share $-0.81 ↘
Trailing P/E —
Price / Book 5.5x
FCF Yield —
Debt / Equity 0.06
info Valuation on last close. End-of-day price, Sep 24, 2026.

19-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$67.48M
↑ +25.2% —
Net Income Profit after all expenses
$-278.67M
↓ -60.2% —
Operating Margin Operating profit as % of sales
-449.9%
↓ -25.5% 0th
FCF / Share Free cash flow per share
$-0.81
↓ -151.9% —
Long-Term Debt Long-term obligations
$9.70M
↑ +1.9% —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↓
1
Returns ↓
4
Financial Health →
47
Cash Quality ↓
31

bar_chart Data from SEC EDGAR XBRL filings

Synced 2 days ago 19 years · 70 quarters